Davenport AP - Search Results

1

Endothelin: progress in pharmacology and physiology.

Haynes WG, Davenport AP, Webb DJ. Haynes WG, et al. Among authors: davenport ap. Trends Pharmacol Sci. 1993 Jun;14(6):225-8. doi: 10.1016/0165-6147(93)90012-9. Trends Pharmacol Sci. 1993. PMID: 8372400 No abstract available.

2

Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans?

Davenport AP, Maguire JJ. Davenport AP, et al. Trends Pharmacol Sci. 1994 Jan;15(1):9-11. doi: 10.1016/0165-6147(94)90120-1. Trends Pharmacol Sci. 1994. PMID: 8140658 Review. No abstract available.

3

Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm.

Plumpton C, Haynes WG, Webb DJ, Davenport AP. Plumpton C, et al. Among authors: davenport ap. Br J Pharmacol. 1995 Sep;116(2):1821-8. doi: 10.1111/j.1476-5381.1995.tb16669.x. Br J Pharmacol. 1995. PMID: 8528566 Free PMC article.

4

Measurement of C-terminal fragment of big endothelin-1: a novel method for assessing the generation of endothelin-1 in humans.

Plumpton C, Haynes WG, Webb DJ, Davenport AP. Plumpton C, et al. Among authors: davenport ap. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S34-6. J Cardiovasc Pharmacol. 1995. PMID: 8587408

5

The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044.

Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP. Plumpton C, et al. Among authors: davenport ap. Br J Pharmacol. 1996 Sep;119(2):311-4. doi: 10.1111/j.1476-5381.1996.tb15987.x. Br J Pharmacol. 1996. PMID: 8886414 Free PMC article. Clinical Trial.

6

Urotensin II: fish neuropeptide catches orphan receptor.

Davenport AP, Maguire JJ. Davenport AP, et al. Trends Pharmacol Sci. 2000 Mar;21(3):80-2. doi: 10.1016/s0165-6147(00)01449-8. Trends Pharmacol Sci. 2000. PMID: 10689357 Review. No abstract available.

7

Endothelin receptor antagonism in patients with chronic heart failure.

Love MP, Ferro CJ, Haynes WG, Plumpton C, Davenport AP, Webb DJ, McMurray JJ. Love MP, et al. Among authors: davenport ap. Cardiovasc Res. 2000 Jul;47(1):166-72. doi: 10.1016/s0008-6363(00)00081-x. Cardiovasc Res. 2000. PMID: 10869543

8

Of mice and men: advances in endothelin research and first antagonist gains FDA approval.

Davenport AP, Maguire JJ. Davenport AP, et al. Trends Pharmacol Sci. 2002 Apr;23(4):155-7. doi: 10.1016/s0165-6147(00)01975-1. Trends Pharmacol Sci. 2002. PMID: 11931980 No abstract available.

9

Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt.

Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, Yanagisawa M, Webb DJ, Kotelevtsev YV. Bagnall AJ, et al. Among authors: davenport ap. Hypertension. 2006 Aug;48(2):286-93. doi: 10.1161/01.HYP.0000229907.58470.4c. Epub 2006 Jun 26. Hypertension. 2006. PMID: 16801484

10

Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease.

Dhaun N, Ferro CJ, Davenport AP, Haynes WG, Goddard J, Webb DJ. Dhaun N, et al. Among authors: davenport ap. Nephrol Dial Transplant. 2007 Nov;22(11):3228-34. doi: 10.1093/ndt/gfm364. Epub 2007 Jun 7. Nephrol Dial Transplant. 2007. PMID: 17556408 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

289 results

Search Page